Literature DB >> 12497000

Distribution of vascular endothelial growth factor (VEGF) in prostate disease.

K Walsh1, S Sriprasad, D Hopster, J Codd, D Mulvin.   

Abstract

Vascular endothelial growth factor (VEGF) is a heparin-binding polypeptide growth factor. It is a potent mitogen for endothelial cells. Immunohistochemical localisation of VEGF was performed on 25 moderate to poorly differentiated stage T4 M+ prostate cancer specimens and 30 benign prostatic hyperplasia (BPH) specimens. A positive result was indicated by area staining >25% and +2 or +3 staining intensity. Positive epithelial staining was observed in 50% of BPH specimens and 56% of cancer specimens, while positive stromal staining was observed in 73% of BPH specimens and 30% of cancer specimens. This may reflect an active role for stromal VEGF in the pathological process of BPH.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12497000     DOI: 10.1038/sj.pcan.4500575

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  10 in total

1.  Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue.

Authors:  Gulsah Kaygusuz; Ozden Tulunay; Sumer Baltaci; Orhan Gogus
Journal:  Int Urol Nephrol       Date:  2006-12-16       Impact factor: 2.370

Review 2.  An introduction to acinar pressures in BPH and prostate cancer.

Authors:  Panikar Wadhera
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

3.  An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer.

Authors:  Robert E Lenkinski; B Nicolas Bloch; Fangbing Liu; John V Frangioni; Sven Perner; Mark A Rubin; Elizabeth M Genega; Neil M Rofsky; Sandra M Gaston
Journal:  MAGMA       Date:  2008-08-28       Impact factor: 2.310

4.  Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels.

Authors:  Won Tae Kim; Seok Joong Yun; Young Deuk Choi; Gi-Young Kim; Sung-Kwon Moon; Yung Hyun Choi; Isaac Yi Kim; Wun-Jae Kim
Journal:  J Korean Med Sci       Date:  2011-09-01       Impact factor: 2.153

5.  Prostatic hyperplasia: Vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy.

Authors:  Daniel S R Angrimani; Maria Claudia P Francischini; Maíra M Brito; Camila I Vannucchi
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240

6.  Cigarette smoke induces nuclear translocation of heme oxygenase 1 (HO-1) in prostate cancer cells: nuclear HO-1 promotes vascular endothelial growth factor secretion.

Authors:  Gabriel Birrane; Huchun Li; Suping Yang; Souvenir D Tachado; Seyha Seng
Journal:  Int J Oncol       Date:  2013-04-17       Impact factor: 5.650

7.  Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610.

Authors:  Larry Pan; Seunghee Baek; Pamela R Edmonds; Mack Roach; Harvey Wolkov; Satish Shah; Alan Pollack; M Elizabeth Hammond; Adam P Dicker
Journal:  Radiat Oncol       Date:  2013-04-25       Impact factor: 3.481

8.  Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice.

Authors:  Liang-Yun Zhao; Xiao-Peng Mao; Kai-Yuan Chao; Sheng-Jie Guo; Shao-Peng Qiu
Journal:  Braz J Med Biol Res       Date:  2012-05-17       Impact factor: 2.590

9.  PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy.

Authors:  Maxim Rybalov; Hildo J K Ananias; Hilde D Hoving; Henk G van der Poel; Stefano Rosati; Igle J de Jong
Journal:  Int J Mol Sci       Date:  2014-04-10       Impact factor: 5.923

10.  Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies.

Authors:  Josué Rivera-Pérez; María Del Rocío Monter-Vera; Cornelio Barrientos-Alvarado; Julia D Toscano-Garibay; Teresa Cuesta-Mejías; Javier Flores-Estrada
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.